Heartware International (NASDAQ:HTWR), which was on a tear throughout 2010 from their highly successful HVAD device.
Wedbush noted, "HeartWare enjoyed a very successful 2010 as the company’s HVAD device quickly became viewed as the favorite LVAD among surgeons and investors alike. The company then validated this perspective by releasing overwhelmingly positive data from its pivotal US trial in Bridge-to-Transplant in November."
Heartware International also announced they've filled a PMA for approval of the HVAD in Brindge-to-Transplant. Approval in the U.S. is expected to come sometime in the fourth quarter of 2011.
Wedbush maintains their "Outperform" rating on Heartware International, which closed Wednesday at $88.66, gaining $1.16, or 1.33 percent. They raised their price target on them from $80 to $100.
No comments:
Post a Comment